1997
DOI: 10.1128/jvi.71.12.9427-9433.1997
|View full text |Cite
|
Sign up to set email alerts
|

The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity

Abstract: The spike protein (S) of the murine coronavirus mouse hepatitis virus strain A59 (MHV-A59) induces both virus-to-cell fusion during infection and syncytium formation. Thus far, only syncytium formation could be studied after transient expression of S. We have recently described a system in which viral infectivity is mimicked by using virus-like particles (VLPs) and reporter defective-interfering (DI) RNAs (E. C. W. Bos, W.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
31
0

Year Published

2000
2000
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(32 citation statements)
references
References 53 publications
1
31
0
Order By: Relevance
“…We selected this region of the MHV-A59 S protein for our initial studies and created a plasmid, designated pCAGGS-S (546-548), for expressing a mutant S protein in which residues R546/C547/Q548 were changed to alanine. To determine the effect that this mutation had on the overall conformation of the protein we compared its expression and its immunoreactivity with two different conformationally sensitive anti-S monoclonal antibodies, known to neutralize MHV-A59 infectivity and block infection with virus like particles containing the MHV-A59 structural proteins (Gilmore et al, 1987;Bos et al, 1997) compared to that of wild type S protein expressed in the same vector. Replicate cultures of 293 T cells were transfected with pCAGGS-S or pCAGGS-S (546-548) and after 24 h post transfection the cells were metabolically labeled with 35 S (cysteine and methionine) for 9 h, harvested, cytoplasmic extracts prepared and then immunoprecipitated with the anti-spike monoclonal neutralizing antibodies A2.1 and A2.3 (Gilmore et al, 1987) or with a polyclonal rabbit antispike antibody, B46 (kindly provided by Dr. John Fleming and Dr. K. Holmes, respectively).…”
Section: Alanine Substitution Of Cysteine 547 Facilitates Partial Recmentioning
confidence: 99%
“…We selected this region of the MHV-A59 S protein for our initial studies and created a plasmid, designated pCAGGS-S (546-548), for expressing a mutant S protein in which residues R546/C547/Q548 were changed to alanine. To determine the effect that this mutation had on the overall conformation of the protein we compared its expression and its immunoreactivity with two different conformationally sensitive anti-S monoclonal antibodies, known to neutralize MHV-A59 infectivity and block infection with virus like particles containing the MHV-A59 structural proteins (Gilmore et al, 1987;Bos et al, 1997) compared to that of wild type S protein expressed in the same vector. Replicate cultures of 293 T cells were transfected with pCAGGS-S or pCAGGS-S (546-548) and after 24 h post transfection the cells were metabolically labeled with 35 S (cysteine and methionine) for 9 h, harvested, cytoplasmic extracts prepared and then immunoprecipitated with the anti-spike monoclonal neutralizing antibodies A2.1 and A2.3 (Gilmore et al, 1987) or with a polyclonal rabbit antispike antibody, B46 (kindly provided by Dr. John Fleming and Dr. K. Holmes, respectively).…”
Section: Alanine Substitution Of Cysteine 547 Facilitates Partial Recmentioning
confidence: 99%
“…The requirement for proteolytic maturation among the normally cleaved S glycoproteins of the group 2 CoV species is likewise ambiguous. In the MHV glycoprotein, mutations that alter the furin protease recognition sequence (R-X-R/K-R↓; (Molloy et al, 1999;Rockwell et al, 2002) and references therein) and prevent cleavage generally diminish cell-cell fusion activity (Bos et al, 1995;de Haan et al, 2004;Sturman et al, 1985;Taguchi, 1993;Yamada et al, 1998), yet do not markedly affect viral infectivity or pathogenesis (Bos et al, 1997;de Haan et al, 2004;Hingley et al, 2002). By contrast, MHV infectivity can be enhanced by exogenous treatment with trypsin (Sturman et al, 1985), raising the possibility that proteases that recognize single basic residues may be important.…”
Section: Introductionmentioning
confidence: 99%
“…The S glycoprotein is primarily responsible for entry of all coronaviruses into susceptible cells through binding to specific receptors on cells and mediating subsequent virus-cell fusion (Cavanagh, 1995). The S glycoprotein specified by mouse hepatitis virus (MHV) is cleaved into S1 and S2 subunits, although cleavage is not necessarily required for virus-cell fusion (Bos et al, 1997;Gombold et al, 1993;Stauber et al, 1993). Similarly, the SARS-CoV S glycoprotein seems to be cleaved into S1 and S2 subunits in Vero-E6-infected cells , while it is not known whether this cleavage affects S-mediated cell fusion.…”
Section: Introductionmentioning
confidence: 99%